OpenURL Connection Search

Select item for more details and to access through your institution.

The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma.
Published in:
British Journal of Haematology, 2021, v. 195, n. 3, p. 405, doi. 10.1111/bjh.17738
By:
- Lutfi, Forat;
- Holtzman, Noa G.;
- Kansagra, Ankit J.;
- Mustafa Ali, Moaath;
- Bukhari, Ali;
- Yan, Jingsheng;
- Samanta, Santanu;
- Gottlieb, David;
- Kim, Dong W.;
- Matsumoto, Lisa R.;
- Gahres, Natalie;
- Ruehle, Kathleen;
- Lee, Seung T.;
- Law, Jennie Y.;
- Kocoglu, Mehmet H.;
- Atanackovic, Djordje;
- Yared, Jean A.;
- Hardy, Nancy M.;
- Molitoris, Jason;
- Mohindra, Pranshu
Publication type:
Article
Chimeric antigen receptor T‐cell therapy after allogeneic stem cell transplant for relapsed/refractory large B‐cell lymphoma.
Published in:
British Journal of Haematology, 2021, v. 192, n. 1, p. 212, doi. 10.1111/bjh.17121
By:
- Lutfi, Forat;
- Holtzman, Noa;
- Siglin, Jonathan;
- Bukhari, Ali;
- Mustafa Ali, Moaath;
- Kim, Dong;
- Sanchez‐Petitto, Gabriela;
- Gottlieb, David;
- Ruehle, Kathleen;
- Hutnick, Elizabeth;
- Gahres, Natalie;
- Hankey, Kim;
- Lee, Seung;
- Kocoglu, Mehmet;
- Yared, Jean;
- Hardy, Nancy;
- Rapoport, Aaron;
- Dahiya, Saurabh
Publication type:
Article
Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Published in:
Neuro-Oncology, 2021, v. 23, n. 1, p. 112, doi. 10.1093/neuonc/noaa183
By:
- Holtzman, Noa G;
- Xie, Hao;
- Bentzen, Soren;
- Kesari, Vivek;
- Bukhari, Ali;
- Chaer, Firas El;
- Lutfi, Forat;
- Siglin, Jonathan;
- Hutnick, Elizabeth;
- Gahres, Natalie;
- Ruehle, Kathleen;
- Ahmad, Haroon;
- Shanholtz, Carl;
- Kocoglu, Mehmet H;
- Badros, Ashraf Z;
- Yared, Jean A;
- Hardy, Nancy M;
- Rapoport, Aaron P;
- Dahiya, Saurabh
Publication type:
Article

Found: 3

The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma.

Chimeric antigen receptor T‐cell therapy after allogeneic stem cell transplant for relapsed/refractory large B‐cell lymphoma.

Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.